

Attorney Docket No. 10356.204-US

PATENT

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO.: **PCT/DK2004/000426**

INTERNATIONAL FILING DATE: **June 18, 2004**

PRIORITY DATE: **June 19, 2003**

TITLE: Phospholipase Variants

APPLICANT(S) FOR RO/US: Patkar et al.

EXPRESS MAIL CERTIFICATE

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Express Mail Label No. **EV 421376209 US**

Date of Deposit: December 19, 2005


I hereby certify that the following attached papers or fee

1. Transmittal Letter to the DO/EO/US (in duplicate)
2. Executed Combined Declaration and Power of Attorney
3. Application Data Sheet
4. Preliminary Amendment
5. Paper Copy of Sequence Listing
6. Disk Containing Sequence Listing
7. Information Disclosure Statement
8. Form PTO/SB/08A
9. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the address indicated above.

Julie Tabarovsky

(Name of person mailing paper(s) or fee)



(Signature of person mailing paper(s) or fee)

Mailing Address:

Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097


12-21-05

10/5614847/\$

IAP4 Rec'd PCT/PTO 20 DEC 2005

Attorney Docket No.: 10356.204-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE
(DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 35 U.S.C. 371 of the international application identified below:

INTERNATIONAL APPLICATION NO. PCT/DK2004/000426		INTERNATIONAL FILING DATE 06/18/2004
APPLICANT(S)/INVENTOR(S)		
First Name	Middle Name	Family Name
1.Shamkant 2.Don 3.Tine 4.Jesper 5.Sabry 6.Thomas	1.Anant 2. 3.Muxoll 4. 5. 6.Lykke	1.Patkar 2.Higgins 3.Fatum 4.Vind 5.Madkor 6.Sorensen
TITLE OF THE INVENTION		
Phospholipase Variants		

- This is a first submission of items concerning a filing under 35 U.S.C. 371.
- This is an express request to begin national examination procedures (35 U.S.C. 371(f)).
- The US has been elected.
- A copy of the International Application as filed (35 U.S.C. 371(c)(2)) has been communicated by the International Bureau. The application contains the following parts:

Specification	10 Pages
Abstract	1 Pages
Sequence Listing	19 Pages
Drawings	2 Pages
Total	32 Pages

- Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) have not been made; however, the time limit for making such amendments has NOT expired.

6. An application data sheet is enclosed.
7. The benefit of U.S. provisional application no. 60/479,647 filed on June 19, 2003 is claimed under 35 U.S.C. 119(e).
8. An oath or declaration of the inventors is submitted herewith.
9. An Information Disclosure Statement is submitted herewith.
10. A Preliminary Amendment is submitted herewith.
11. Applicants enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same.
12. The assignee of the present application is:

Novozymes A/S
Krogshoejvej 36
DK-2880 Bagsvaerd
Denmark

Novozymes North America, Inc.
77 Perry Chapel Church Road,
P.O. Box 576
Franklinton, NC 27525
US

Chr. Hansen A/S
Boge Alle 10-12
DK-2970 Horsholm
Denmark

Applicants request that the assignee information be included in the published patent application.

13. Direct all correspondence to Customer Number 25908.
14. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Basic Fee:	\$300.00
Examination Fee:	\$200.00
Search Fee:	\$500.00
Size Fee (\$250 for each 50 pages above 100)	\$0.00

CLAIMS FEE

Total Claims: 13 - 20 = 0 x 50 =	\$0.00
Independent Claims: 2 - 3 = 0 x 200 =	\$0.00
Total Claims Fee:	\$0.00

TOTAL NATIONAL FEE	\$1,000.00
---------------------------	-------------------

15. Please charge the required fee, estimated to be \$1,000, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 19, 2005



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097